论文部分内容阅读
[目的]观察不同剂量贝伐单抗对肿瘤局部炎症因子表达的影响。[方法]接种人结肠癌DLD-1细胞的裸鼠24只,随机分为4组。对照组采用0.9%生理盐水,试验1组2.5mg/kg贝伐单抗,试验2组采用5mg/kg贝伐单抗,试验3组采用10mg/kg贝伐单抗,均分别于第1、5、9d注射。第10d处死裸鼠,留取皮下肿瘤。观察4组间肿瘤大小及肿瘤组织内炎症因子IL-1β、TNF-α、PGE-23 m RNA表达的差异。[结果 ]对照组及3个试验组间肿瘤体积比较差异无统计学意义。试验3组肿瘤组织内IL-1βm RNA表达的抑制最明显,与其他3组比较均有统计学差异(P=0.022、0.043、0.022);试验3组肿瘤组织内TNF-αm RNA表达的抑制最明显,与对照组、试验2组比较差异有统计学意义(P=0.046、0.004);PGE-23 m RNA表达与贝伐单抗的使用无相关性。[结论]10mg/kg贝伐单抗治疗后肿瘤组织内炎症指标IL-1β、TNF-αm RNA的表达明显下降,提示贝伐单抗能抑制肿瘤局部炎症反应。
[Objective] To observe the effect of different doses of bevacizumab on the expression of tumor local inflammatory cytokines. [Method] Twenty-four nude mice inoculated with human colon cancer DLD-1 cells were randomly divided into 4 groups. The control group received 0.9% saline, group 1 2.5mg / kg bevacizumab, group 2 were treated with 5mg / kg bevacizumab, group 3 were treated with bevacizumab 10mg / kg, 5,9 d injection. The nude mice were sacrificed on the 10th day and the subcutaneous tumors were taken. The difference of tumor size and the expression of inflammatory cytokines IL-1β, TNF-α, PGE-23 m RNA between the four groups were observed. [Results] There was no significant difference in tumor volume between the control group and the three experimental groups. The inhibition of IL-1βmRNA expression in the tumor tissue of the experimental group 3 was the most obvious, with statistical significance (P = 0.022,0.043,0.022) compared with the other three groups; the inhibition of TNF-αmRNA expression in the tumor tissue of the experimental group 3 was the most Obviously, compared with the control group and experimental group 2, the difference was statistically significant (P = 0.046, 0.004); PGE-23 mRNA expression was not related to the use of bevacizumab. [Conclusion] The expression of inflammatory markers IL-1β and TNF-αmRNA in the tumor tissue after 10mg / kg bevacizumab treatment significantly decreased, suggesting that bevacizumab can inhibit tumor local inflammatory response.